MADISON, Wis., Oct. 25, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation ...
SHREVEPORT, La. -- No one likes to get a colonoscopy, but it's an important tool in the fight against colon cancer. There is an easier way: Cologuard is a non-invasive, effective, and affordable ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
Cologuard is getting an upgrade soon. An updated at-home screening test, called Cologuard Plus, is expected to be available in June 2025. Cologuard Plus is a more sensitive version of the original ...
Modeling data show Cologuard PlusTM test delivers highest life-years gained with fewest number of colonoscopies among noninvasive colorectal cancer (CRC) screening strategies “Exact Sciences is ...
MADISON, Wis., Dec. 20, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, supports recent policy changes that help increase access ...